JACOB AELION
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- JACKSON, TN
- NPI
- 1679551501
- Received
- $492,172 in 1,638 records, 2019 to 2025 ($459,408 general, $32,763 research)
- As principal investigator
- $12,713,192 of research payments to others in 888 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 211 | $51,422 |
| 2024 | General payment | 157 | $26,622 |
| 2024 | Research payment | 1 | $114 |
| 2023 | General payment | 200 | $52,561 |
| 2023 | Research payment | 1 | $128 |
| 2022 | General payment | 224 | $60,766 |
| 2022 | Research payment | 1 | $10 |
| 2021 | General payment | 201 | $32,280 |
| 2021 | Research payment | 2 | $2,196 |
| 2020 | General payment | 247 | $59,308 |
| 2020 | Research payment | 3 | $779 |
| 2019 | General payment | 386 | $176,446 |
| 2019 | Research payment | 4 | $29,535 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 131 | $301,709 |
| Travel and Lodging | 202 | $78,055 |
| Consulting Fee | 15 | $52,408 |
| Research payment | 12 | $32,763 |
| Food and Beverage | 1,263 | $26,026 |
| Honoraria | 1 | $825 |
| Education | 14 | $384 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | Amgen Inc. | $657 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-12-17 | Amgen Inc. | $4 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-12-16 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-12-15 | ABBVIE INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-15 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-15 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-12 | Amgen Inc. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-12 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-11 | Amgen Inc. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-11 | Amgen Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-11 | Amgen Inc. | $110 | Travel and Lodging | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-11 | Amgen Inc. | $89 | Travel and Lodging | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-11 | Amgen Inc. | $6 | Food and Beverage | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-10 | Aurinia Pharma U.S., Inc. | $27 | Food and Beverage | In-kind items and services | LUPKYNIS Drug, LUPUS NEPHRITIS | 2025 | |
| 2025-12-09 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-08 | UCB, Inc. | $27 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-03 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-03 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-02 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-12-02 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-12-01 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-11-26 | Aurinia Pharma U.S., Inc. | $22 | Food and Beverage | In-kind items and services | LUPKYNIS Drug, LUPUS NEPHRITIS | 2025 | |
| 2025-11-25 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | Amgen Inc. | $675 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-18 | Amgen Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-18 | Amgen Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-17 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-13 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-11 | GlaxoSmithKline, LLC. | $22 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-11-05 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-04 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-03 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-10-31 | Amgen Inc. | $775 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-30 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-28 | ABBVIE INC. | $126 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-28 | Janssen Scientific Affairs, LLC | $15 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-26 | E.R. Squibb & Sons, L.L.C. | $73 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-23 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-23 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-21 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-20 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-10-16 | Organon Llc | $16 | Food and Beverage | In-kind items and services | NEXPLANON Drug, ETONOGESTREL | 2025 | |
| 2025-10-06 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-09-30 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-30 | GENZYME CORPORATION | $4 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-09-29 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-09-25 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-25 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-24 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2025 | |
| 2025-09-18 | ABBVIE INC. | $391 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-17 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-16 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-11 | UCB, Inc. | $15 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-09 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-08 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-08 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | ABBVIE INC. | $4,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | ABBVIE INC. | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-04 | Aurinia Pharma U.S., Inc. | $13 | Food and Beverage | In-kind items and services | LUPKYNIS Drug, LUPUS NEPHRITIS | 2025 | |
| 2025-09-03 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-09-02 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-29 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-26 | Amgen Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-26 | Amgen Inc. | $832 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-26 | Amgen Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-25 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-08-21 | Amgen Inc. | $118 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-20 | ABBVIE INC. | $1,577 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-20 | ABBVIE INC. | $176 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-20 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-20 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | ENBREL Biological, Inflammation | 2025 | |
| 2025-08-18 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-14 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-14 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-12 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-08-08 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-07 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-08-05 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-04 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-07-28 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-07-23 | ABBVIE INC. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-14 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-10 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-09 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-07-08 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-07-07 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-06-30 | GENZYME CORPORATION | $33 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-06-26 | Merck Sharp & Dohme LLC | $95 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-06-25 | Aurinia Pharma U.S., Inc. | $17 | Food and Beverage | In-kind items and services | LUPKYNIS Drug, LUPUS NEPHRITIS | 2025 | |
| 2025-06-24 | UCB, Inc. | $22 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-06-24 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-06-23 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-18 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | ENBREL Biological, Inflammation | 2025 | |
| 2025-06-17 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-12 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-06-09 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-06-05 | ABBVIE INC. | $484 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $238 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $196 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $152 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $80 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $55 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $50 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-06-05 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-03 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-06-02 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-05-30 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | ABBVIE INC. | $9 | Education | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | ABBVIE INC. | $9 | Education | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-28 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-27 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-05-21 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-05-20 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-20 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-19 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | ENBREL Biological, Inflammation | 2025 | |
| 2025-05-16 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-05-15 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-15 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-14 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-13 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-07 | UCB, Inc. | $26 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-07 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-05-07 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-07 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-05-06 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-05-05 | Mallinckrodt Hospital Products Inc. | $18 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-04-30 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-30 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-28 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-04-23 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-04-22 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-04-21 | E.R. Squibb & Sons, L.L.C. | $22 | Food and Beverage | Cash or cash equivalent | ORENCIA Biological, Immunology | 2025 | |
| 2025-04-16 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-16 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-13 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-04-10 | Janssen Research & Development, LLC | $168 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-10 | UCB, Inc. | $19 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-09 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-04-07 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-04-03 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | ENBREL Biological, Inflammation | 2025 | |
| 2025-04-03 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-02 | Amgen Inc. | $159 | Travel and Lodging | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-04-02 | Amgen Inc. | $6 | Food and Beverage | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-27 | ABBVIE INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-27 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-03-26 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-03-25 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-25 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-03-25 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-03-20 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | ENBREL Biological, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $1,664 | Travel and Lodging | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-19 | Amgen Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-18 | Amgen Inc. | $103 | Travel and Lodging | Cash or cash equivalent | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-17 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-16 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-13 | Amgen Inc. | $141 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-12 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-10 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-03-10 | UCB, Inc. | $12 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-03-07 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-07 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-06 | Amgen Inc. | $128 | Food and Beverage | In-kind items and services | TAVNEOS Drug, Inflammation | 2025 | |
| 2025-03-05 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-03-04 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-04 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-03 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-03-01 | ABBVIE INC. | $103 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | 2025 | |
| 2025-02-26 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-02-25 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-12 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-02-10 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-02-06 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-05 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-01-27 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | KRYSTEXXA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-01-25 | Janssen Research & Development, LLC | $155 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-25 | Janssen Research & Development, LLC | $64 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-25 | Janssen Research & Development, LLC | $36 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-25 | Janssen Research & Development, LLC | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $236 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $137 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $54 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $36 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-24 | Janssen Research & Development, LLC | $9 | Food and Beverage | In-kind items and services | 2025 |
The latest 200 records of 1,638.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | Janssen Research & Development, LLC | WEST TENNESSEE RESEARCH INSTITUTE | $14,305 | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipoc | 2025 |
| 2025-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTIT | $6,503 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-12-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,156 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-12-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,121 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-12-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $4,385 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-11-28 | Janssen Research & Development, LLC | WEST TENNESSEE RESEARCH INSTITUTE | $7,085 | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipoc | 2025 |
| 2025-11-18 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTIT | $4,461 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-11-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,303 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-11-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,456 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-11-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,852 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-11-04 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTIT | $858 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-10-30 | Janssen Research & Development, LLC | WEST TENNESSEE RESEARCH INSTITUTE | $3,690 | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipoc | 2025 |
| 2025-10-17 | UCB SA | WEST TENNESSEE RESEARCH INSTITUTE | $1,799 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN T | 2025 |
| 2025-10-14 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTIT | $10,943 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-10-09 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $3,921 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-10-09 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $8,815 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-10-09 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,759 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-10-09 | E.R. Squibb & Sons, L.L.C. | WEST TENNESSEE RESEARCH INSTITUTE | $19,117 | Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus | 2025 |
| 2025-10-09 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $13,024 | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Seve | 2025 |
| 2025-10-02 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTIT | $1,906 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $9,747 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $2,296 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-09-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,181 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-09-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,124 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-08-28 | Janssen Research & Development, LLC | WEST TENNESSEE RESEARCH INSTITUTE | $4,492 | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipoc | 2025 |
| 2025-08-26 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE, LLC | $291 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Parti | 2025 |
| 2025-08-19 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $1,790 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-08-05 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,834 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-08-05 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $365 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | WEST TENNESSEE RESEARCH INSTITUTE | $8,815 | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipoc | 2025 |
| 2025-07-22 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $5,349 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-07-17 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $3,250 | An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab In | 2025 |
| 2025-07-02 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $3,592 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-07-02 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $4,822 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-07-02 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $8,637 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $342 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $910 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $359 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $1,238 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $121 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-16 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $87 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-06-10 | Eli Lilly and Company | WEST TENNESSE RESEARCH INSTITUTE | $1,232 | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXE | 2025 |
| 2025-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $2,296 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-06-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $2,271 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-06-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,834 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-05-22 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $8,832 | A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability o | 2025 |
| 2025-05-20 | PFIZER INC. | WEST TENNESSEE RESEARCH INSTITUTE | $6,348 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND 3ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WI | 2025 |
| 2025-05-20 | PFIZER INC. | WEST TENNESSEE RESEARCH INSTITUTE | $6,348 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND 3ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WI | 2025 |
| 2025-05-20 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $9,027 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-05-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $7,028 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-05-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,834 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-05-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,104 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-05-01 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $4,060 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-04-15 | Eli Lilly and Company | WEST TENNESSE RESEARCH INSTITUTE | $72,492 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2025 |
| 2025-04-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,695 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2025 |
| 2025-04-03 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $6,000 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Parti | 2025 |
| 2025-04-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $4,385 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2025 |
| 2025-04-03 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $5,165 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2025 |
| 2025-03-25 | Eli Lilly and Company | WEST TENNESSE RESEARCH INSTITUTE | $1,582 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2025 |
| 2025-03-21 | UCB SA | WEST TENNESSEE RESEARCH INSTITUTE | $13,941 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME | 2025 |
| 2025-03-14 | E.R. Squibb & Sons, L.L.C. | WEST TENNESSEE RESEARCH INSTITUTE | $2,518 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | 2025 |
| 2025-03-11 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $36,914 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-03-10 | Eli Lilly and Company | WEST TENNESSE RESEARCH INSTITUTE | $414 | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2025 |
| 2025-03-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $4,471 | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit | 2025 |
| 2025-03-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,782 | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who | 2025 |
| 2025-03-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $6,681 | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Ad | 2025 |
| 2025-02-25 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE, LLC | $143,521 | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of A | 2025 |
| 2025-02-20 | UCB SA | WEST TENNESSEE RESEARCH INSTITUTE | $66,038 | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-02-05 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $761 | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who | 2025 |
| 2025-02-05 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $9,196 | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit | 2025 |
| 2025-02-05 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,834 | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Ad | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $18,320 | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalu | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $17,719 | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa | 2025 |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | WEST TENNESSEE RESEARCH INSTITUTE | $12,982 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With | 2025 |
| 2025-01-21 | E.R. Squibb & Sons, L.L.C. | WEST TENNESSEE RESEARCH INSTITUTE | $4,436 | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoria | 2025 |
| 2025-01-21 | Takeda Pharmaceuticals U.S.A., Inc. | WEST TENNESSEE RESEARCH INSTITUTE | $8,000 | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safe | 2025 |
| 2025-01-16 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $2,000 | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Saf | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $5,755 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2025 |
| 2025-01-15 | UCB SA | WEST TENNESSEE RESEARCH INSTITUTE | $1 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2025 |
| 2025-01-14 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $320,338 | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and | 2025 |
| 2025-01-08 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $12,353 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2025 |
| 2025-01-06 | Amgen Inc. | WEST TENNESSEE RESEARCH INSTITUTE, LLC | $7,765 | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Particip | 2025 |
| 2025-01-02 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $32,878 | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab | 2025 |
| 2025-01-02 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $2,652 | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian | 2025 |
| 2025-01-02 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $3,936 | M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who | 2025 |
| 2025-01-02 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $4,385 | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $538 | A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy a | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | WEST TENNESSEE RESEARCH INSTITUTE | $69,351 | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolera | 2025 |
| 2024-12-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $1,695 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2024 |
| 2024-12-04 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $21,408 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate | 2024 |
| 2024-11-22 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $33,426 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2024 |
| 2024-11-13 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $7,794 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2024 |
| 2024-11-07 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $6,681 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i | 2024 |
| 2024-11-06 | ABBVIE INC. | WEST TENNESSEE RESEARCH INSTITUTE | $6,860 | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a His | 2024 |
| 2024-11-05 | UCB SA | WEST TENNESSEE RESEARCH INSTITUTE | $4,360 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-11-05 | ABBVIE INC. | WEST TENNESEE RESEARCH INSTITUTE | $1,000 | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2024 |
| 2024-10-22 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $99 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2024 |
| 2024-10-17 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $154,625 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2024 |
| 2024-10-04 | CSL Behring | WEST TENNESSEE RESEARCH INSTITUTE | $9,965 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2024 |
| 2024-09-25 | Eli Lilly and Company | WEST TENNESSE RESEARCH INSTITUTE | $2,247 | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jackson, TN, county Madison County, TN, state Tennessee; placed by its city name.
| Measure | Place (city or town) Jackson, TN | County Madison County, TN | State Tennessee |
|---|---|---|---|
| Population B01003 | 68,435 | 99,295 | 7,066,383 |
| Population, 2020 census P1 | 68,205 | 98,823 | 6,910,840 |
| Median age B01002 | 35.5 | 38.3 | 38.9 |
| Under 18 B01001 | 24.4% | 22.4% | 22.2% |
| 65 and over B01001 | 16.2% | 17.9% | 17.1% |
| Households B11001 | 27,541 | 40,153 | 2,824,277 |
| Foreign born B05002 | 3.9% | 3.7% | 6.1% |
| Median household income B19013 | $53,032 | $60,042 | $69,595 |
| Median family income B19113 | $72,767 | $80,109 | $87,314 |
| Per capita income B19301 | $31,372 | $33,572 | $39,437 |
| Poverty rate B17001 | 22.2% | 18.2% | 13.8% |
| Unemployment rate B23025 | 8.1% | 7.0% | 4.7% |
| Civilian labor force B23025 | 33,179 | 49,233 | 3,527,571 |
| Mean commute (minutes) B08013 | 18.2 | 20.3 | 25.7 |
| Bachelor's degree or higher B15003 | 27.8% | 26.6% | 31.1% |
| Housing units B25001 | 30,324 | 44,091 | 3,143,670 |
| Owner-occupied B25003 | 51.2% | 62.0% | 66.9% |
| Renters B25003 | 48.8% | 38.0% | 33.1% |
| Median home value B25077 | $217,800 | $211,800 | $286,700 |
| Median gross rent B25064 | $1,145 | $1,123 | $1,189 |
| White, not Hispanic B03002 | 45.7% | 53.4% | 71.0% |
| Black B03002 | 44.0% | 36.2% | 15.4% |
| Hispanic or Latino B03002 | 5.1% | 5.2% | 7.4% |
| Asian B03002 | 1.3% | 1.0% | 1.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jackson, TN.
Comments